Post-herpetic Neuralgia: a Review
详细信息    查看全文
Johnson RW, Rice Andrew SC. Postherpetic Neuralgia. N Engl J Med. 2014;371:1526–33. doi:10.​1056/​NEJMcp1403062 . This manuscript exhibit a comprehensive review of the pathophysiology and current management of the subject at hand, postherpetic neuralgia.CrossRef PubMed
4.Civen R, Chaves SS, Jumaan A, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 2009;28(11):954–9.CrossRef PubMed
5.Itzler RF, Insinga RP, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53.CrossRef PubMed PubMedCentral
6.Ferreira M, Sanches M, Teixeira M, Guerra M, Selores M. Persistent varicella as the initial manifestation of systemic lymphoma. Dermatol Online J. 2008;14(2):24.PubMed
7.Fuks L, Shitrit D, Fox BD, et al. Herpes zoster after lung trans- plantation: incidence, timing, and outcome. Ann Thorac Surg. 2009;87(2):423–6.CrossRef PubMed
8.Shin BS, Na CH, Song IG, Choi KC. A case of human immunodeficiency virus infection initially presented with disseminated herpes zoster. Ann Dermatol. 2010;22(2):199–202.CrossRef PubMed PubMedCentral
9.Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748–53.CrossRef PubMed PubMedCentral
10.Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–9 [Erratum, Mayo Clin Proc 2008;83:255.].CrossRef PubMed
11.Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manag. 2004;28(4):396–411.CrossRef
12.Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23–24):3076–90.CrossRef PubMed
13.Ragozzino MW, Melton 3rd LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61(5):310–6.CrossRef
14.Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67:241–51.CrossRef PubMed
15.Watson CPN, Oaklander AL. Postherpetic neuralgia. In: Cervero F, Jensen TS, editors. Pain—handbook of clinical neurology, vol. 81. Edinburgh: Elsevier; 2006. p. 661–77.
16.Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and cutaneous deafferentation after facial shingles. Pain. 2002;96:9–12.CrossRef PubMed
17.Oaklander AL, Bowsher D, Galer B, Haanpaa M, Jensen MP. Herpes zoster itch: preliminary epidemiologic data. J Pain. 2003;4:338–43.CrossRef PubMed
18.Daniel HC, Narewska J, Serpell M, Hoggart B, Johnson R, Rice AS. Comparison of psychological and physical function in neuropathic pain and nociceptive pain: implications for cognitive behavioral pain management programs. Eur J Pain. 2008;12:731–41. 14.CrossRef PubMed
19.Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26:656–66.PubMed
20.Srinivas N, Patricia M-F. Diagnosing and managing postherpetic neuralgia. Drugs Aging. 2012;29:863–9.CrossRef
21.Head H, Campbell A. The pathology of herpes zoster and its bearing on sensory localisation. Brain. 1900;23:353–532.CrossRef
22.Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology. 2001;95(1):241–9.CrossRef PubMed
23.Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A. 1999;96(14):7723–30.CrossRef PubMed PubMedCentral
24.Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms and treatment. Lancet Neurol. 2010;9(8):807–19.CrossRef PubMed
25.Garry EM, Delaney A, Anderson HA, et al. Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitization that is attenuated by gabapentin or sodium channel blocking drugs. Pain. 2005;118(1–2):97–111.CrossRef PubMed
26.Watson CP, Deck JH, Morshead C, Van der Kooy D, Evans RJ. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain. 1991;44:105–17.CrossRef PubMed
27.Dastidar P, Haanpää M, Weinberg A, Levin M, Miettinen A, Lapinlampi A, et al. CSF and MRI findings in patients with acute herpes zoster. Neurology. 1998;51:1405–11.CrossRef PubMed
28.Opstelten W, McElhaney J, Weinberger B, Oaklander AL, Johnson R. The impact of varicella zoster virus: chronic pain. J Clin Virol. 2010;48:S8–S13.CrossRef PubMed
29.Haanpää M, Häkkinen V, Nurmikko T. Motor involvement in acute herpes zoster. Muscle Nerve. 1997;20:1433–8.CrossRef PubMed
30.Louise OA. Mechanisms of pain and itch caused by herpes zoster (shingles). J Pain. 2008;9(1 Suppl 1):S10–8.
31.Fields H, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5(4):209–27.CrossRef PubMed
32.Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain. 2001;92:139–45.CrossRef PubMed
33.Dworkin RH, Gnann Jr JW, Oaklander A, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008;9(1 suppl 1):S37–44.CrossRef PubMed
34.Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337–44.CrossRef PubMed
35.••
Harden RN, Kaye AD, Kintanar T, Argoff CE. Evidence-based guidance for the management of postherpetic neuralgia in primary care. Postgrad Med. 2013;125(4):191–202. doi:10.​3810/​pgm.​2013.​07.​2690 . This manuscript exhibit a comprehensive review of the pathophysiology and current management of the subject at hand, postherpetic neuralgia.CrossRef PubMed
36.Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27(5):417–33. doi:10.​2165/​11536540-000000000-00000 . Review.CrossRef PubMed
37.Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–14. Review.CrossRef PubMed PubMedCentral
38.American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. Pain Med. 2009;10(6):1062–83.
39.Hadjistavropoulos T, Herr K, Turk DC, Fine PG, Dworkin RH, Helme R, Jackson K, Parmelee PA, Rudy TE, Lynn Beattie B, Chibnall JT, Craig KD, Ferrell B, Ferrell B, Fillingim RB, Gagliese L, Gallagher R, Gibson SJ, Harrison EL, Katz B, Keefe FJ, Lieber SJ, Lussier D, Schmader KE, Tait RC, Weiner DK, Williams J. AAN (American Academy of Neurology). 2011. Clinical Practice Guideline Process Manual, 2011 Ed. St. Paul, MN: The American Academy of Neurology Clin J Pain. 2007;23(1 Suppl):S1-43.
40.Max MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol. 1994;35(suppl):S50–3.CrossRef PubMed
41.Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213–24.CrossRef PubMed PubMedCentral
42.Thomas BM, Farquhar-Smith P. Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults. Ther Clin Risk Manag. 2013;9:469–75. doi:10.​2147/​TCRM.​S50212 .PubMed PubMedCentral
43.Cappuzzo KA. Treatment of postherpetic neuralgia: focus on pregabalin. Clin Interv Aging. 2009;4:17–23.PubMed PubMedCentral
44.Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;3, CD007076. Review.PubMed
  • 作者单位：Graham R. Hadley (1)
    Julie A. Gayle (1)
    Juan Ripoll (1)
    Mark R. Jones (1)
    Charles E. Argoff (2)
    Rachel J. Kaye (3)
    Alan D. Kaye (1)

    1. Department of Anesthesiology, Louisiana State University Health Sciences Center, Room 656, 1542 Tulane Ave., New Orleans, LA, USA
    2. Department of Neurology, Albany Medical College, Comprehensive Pain Center, Albany Medical Center, 43 New Scotland Avenue, MC 70, Albany, NY, USA
    3. Department of Biochemistry, Bowdoin College, Brunswick, ME, USA
  • 刊物主题：Pain Medicine; Internal Medicine;
  • 出版者：Springer US
  • ISSN：1534-3081
    • 文摘
    Post-herpetic neuralgia (PHN) is a chronic neuropathic pain condition that persists 3 months or more following an outbreak of shingles. Shingles, also known as acute herpes zoster, is associated with the reactivation of the dormant varicella zoster virus in an individual who has experienced chicken pox. PHN is associated with persistent and often refractory neuropathic pain. Patients may experience multiple types of pain including a constant deep, aching, or burning pain; a paroxysmal, lancinating pain; hyperalgesia (painful stimuli are more painful than expected); and allodynia (pain associated with typically non-painful stimuli). The pharmacological treatment of PHN may include a variety of medications including alpha-2 delta ligands (gabapentin and pregabalin), other anticonvulsants (carbamazepine), tricyclic antidepressants (amitriptyline, nortriptyline, doxepin), topical analgesics (5 % lidocaine patch, capsaicin) tramadol, or other opioids. The considerable side effect profiles of the commonly used oral medications often limit their practical use, and a combination of both topical and systemic agents may be required for optimal outcomes. Physicians and other treatment providers must tailor treatment based on the response of individual patients.
    NGLC 2004-2010.National Geological Library of China All Rights Reserved.
    Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
    For exchange or info please contact us via email.